Gastritis may be healed with adequate therapy, hence the need for gastritis treatment is expected to grow in the near future. The rising frequency of chronic gastritis, particularly in the senior population, bodes well for the gastritis treatment industry. The gastritis therapy market is extremely fragmented. Many corporations are investing extensively in research and development in order to create new therapies for the condition. In the current environment, North America has the largest market share. Gastritis is becoming more common as a result of excessive alcohol intake, as well as a poor lifestyle and diet. However, Asia Pacific is predicted to be a profitable market for gastritis treatment market growth.
Key Competitors in the Gastritis Treatment Industry:
1. Otsuka Indonesia PT
PT Otsuka Indonesia was established in 1974 as a joint venture pharmaceutical company with Otsuka Pharmaceutical Co., Ltd., Japan.Build over a land area of around 40.000 square meters at Lawang, a small town in East Java, the Factory of PT. Otsuka Indonesia manufactures and promotes 4 (four) product groups, namely: Therapeutics Drug, Clinical Nutrition and I.V. Solution, Medical Devices, IV SET. As for now, our Head Office is in South Jakarta.
2. AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. In June 2020, AstraZeneca announced its collaboration with Accent Therapeutics to discover, develop, and commercialize transformative therapeutics targeting RNA-modifying proteins for the treatment of cancer.
3. Zydus Cadila Healthcare Limited
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. Founded in 1952, headquartered in Gujarat, India
4. Novartis AG
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. In January 2020, Novartis AG announced that it had completed acquisition of The Medicines Company, a pharmaceutical company.
*Definition- Gastritis is a condition that causes irritation, inflammation, or erosion of the stomach lining. Gastritis can be either acute or chronic. Some signs of the condition may be present, while others may remain latent.
